Fisseha Tesfaye

发表

Baseline characteristics and treatment outcomes for men with acquired or lifelong premature ejaculation with mild or no erectile dysfunction: integrated analyses of two phase 3 dapoxetine trials.

S. Bull, I. Sharlip, C. McMahon, 2010, The journal of sexual medicine.

Efficacy and safety of dapoxetine in men with premature ejaculation and concomitant erectile dysfunction treated with a phosphodiesterase type 5 inhibitor: randomized, placebo-controlled, phase III study.

W. Hellstrom, S. Bull, F. Giuliano, 2013, The journal of sexual medicine.

Efficacy and safety of dapoxetine for the treatment of premature ejaculation: integrated analysis of results from five phase 3 trials.

C. McMahon, M. Rothman, S. Levine, 2011, The journal of sexual medicine.

Validity of the patient-reported Clinical Global Impression of Change as a measure of treatment response in men with premature ejaculation.

S. Bull, R. Rosen, M. Rothman, 2010, The journal of sexual medicine.

Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries.

F. Giuliano, M. Rothman, D. Rivas, 2009, European urology.

Treatment benefit of dapoxetine for premature ejaculation: results from a placebo‐controlled phase III trial

R. Rosen, D. Rivas, J. Kaufman, 2009, BJU international.

Perceived control over ejaculation is central to treatment benefit in men with premature ejaculation: results from phase III trials with dapoxetine

D. Patrick, S. Bull, M. Rothman, 2008, BJU international.

Addendum to: “Dapoxetine for the Treatment of Premature Ejaculation: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial in 22 Countries” [Eur Urol 2009;55:957–68]

F. Giuliano, M. Rothman, D. Rivas, 2009 .

ORIGINAL RESEARCH—EJACULATORY DISORDERS Treatment of Premature Ejaculation in the Asia-Pacific Region: Results from a Phase III Double-blind, Parallel-group Study of Dapoxetine

C. McMahon, M. Rothman, N. Park, 2010 .

Effects of JNJ-54452840, an Anti-ÃÂ²1 Receptor Antibody Cyclopeptidein Heart Failure Patients: A Randomized, Double-blind, Parallel-group,Phase-2 Pilot Study

Rol, M. Lohse, G. Ertl, 2016 .

Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors.

A. Oza, E. Rubin, M. Hubert, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PATIENT REPORTED OUTCOMES AND IMPROVEMENTS IN INTRAVAGINAL EJACULATORY LATENCY TIME IN DAPOXETINE-TREATED MEN WITH LIFELONG OR ACQUIRED PREMATURE EJACULATION: PHASE 3 POOLED ANALYSES

I. Sharlip, C. McMahon, M. Rothman, 2009 .

LACK OF WITHDRAWAL SYNDROME OR EFFECTS ON ANXIETY WITH DAPOXETINE (DPX) FOR THE TREATMENT OF PREMATURE EJACULATION (PE): RESULTS FROM 2 PHASE III TRIALS

R. Rosen, F. Giuliano, M. Rothman, 2008 .

EFFECTS OF DAPOXETINE (DPX) FOR THE TREATMENT OF PREMATURE EJACULATION (PE) ON THE ERECTILE FUNCTION AND SCALES OF MOOD AND AFFECT

M. Rothman, D. Rivas, R. Mudumbi, 2008 .

Efficacy and safety of dapoxetine for the treatment of premature ejaculation: integrated analysis of results from five phase 3 trials.

C. McMahon, M. Rothman, S. Levine, 2011, Journal of Sexual Medicine.

ORIGINAL RESEARCH—EJACULATORY DISORDERS Treatment of Premature Ejaculation in the Asia-Pacific Region: Results from a Phase III Double-blind, Parallel-group Study of Dapoxetine

C. McMahon, M. Rothman, N. Park, 2010 .